Physician profile
William J Long
NPI 1992778906
$65,675.98
in general payments reported to CMS, 2019-2025
69 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $1,233 · 2021: $2,133 · 2022: $4,533 · 2023: $20K · 2024: $18K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $18K · Food and Beverage: $7,570 · Travel and Lodging: $6,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,516.00 |
| Consulting Fee | $18,000.00 |
| Food and Beverage | $7,570.17 |
| Travel and Lodging | $6,326.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $49,282.16 | 2022-2025 | Ingrezza |
| Intuity Medical INC | $3,013.72 | 2022 | |
| Novo Nordisk INC | $1,089.57 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,050.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $996.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Intuitive Surgical, INC. | $980.26 | 2023 | Da Vinci Surgical System |
| Bausch Health US, LLC | $733.49 | 2020-2025 | Wellbutrin, Aplenzin |
| Novartis Pharmaceuticals Corporation | $692.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $580.61 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $567.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $448.51 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $386.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.06 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $361.82 | 2020-2025 | Nexletol |
| Eisai INC. | $353.60 | 2020-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $332.34 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $315.32 | 2020-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $311.74 | 2019-2022 | |
| Amgen INC. | $309.94 | 2019-2025 | Otezla, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $288.63 | 2023-2025 | Quviviq, Tryvio |
| Avanir Pharmaceuticals, INC. | $282.07 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.93 | 2019-2023 | Trulance, Xifaxan |
| Exact Sciences Corporation | $185.34 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $181.72 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $150.41 | 2020-2021 | |
| Abbott Laboratories | $148.03 | 2023-2025 | Freestyle Libre 3, Eterna, Freestyle Libre 2 |
| Forte Bio-Pharma LLC | $128.77 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Arbor Pharmaceuticals, INC. | $106.50 | 2021 | |
| Merz North America, INC. | $103.60 | 2019 | |
| Azurity Pharmaceuticals, INC. | $98.44 | 2023-2024 | Edarbi, Horizant, Edarbi |
| Convatec INC. | $93.66 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $92.18 | 2021-2025 | Austedo Xr, Austedo Xr |
| Sanofi-Aventis U.S. LLC | $87.10 | 2019-2020 | |
| Horizon Therapeutics Plc | $84.27 | 2022-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $82.14 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Alkermes, INC. | $76.24 | 2023-2024 | Aristada, Lybalvi |
| Argenx US, INC. | $71.71 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $64.03 | 2022-2025 | |
| Ardelyx, INC. | $62.80 | 2025 | Ibsrela |
| Jazz Pharmaceuticals INC. | $60.06 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.69 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $56.08 | 2022-2025 | Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $55.67 | 2023-2024 | Gemtesa, Aptiom |
| Cmp Pharma, INC. | $55.44 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.74 | 2025 | Rexulti |
| Urovant Sciences INC | $45.04 | 2021-2022 | |
| Allergan, INC. | $44.84 | 2020 | |
| Tms Neurohealth Centers INC. | $37.67 | 2025 | Tms Neurohealth Centers INC. |
| Viatris Specialty LLC | $35.26 | 2025 | Yupelri |
| Indivior INC. | $35.10 | 2024 | Perseris |
| Daiichi Sankyo INC. | $34.51 | 2023 | Injectafer |
| Tolmar, INC. | $34.10 | 2025 | Jatenzo |
| Zimmer Biomet Holdings, INC. | $28.74 | 2025 | Persona |
| Phathom Pharmaceuticals, INC. | $27.48 | 2024 | Voquezna |
| Biogen, INC. | $22.14 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.34 | 2022 | |
| Medtronic, INC. | $19.27 | 2021 | |
| C2n Diagnostics, LLC | $18.52 | 2025 | Precivityad2 |
| Inspire Medical Systems, INC. | $17.87 | 2025 | Inspire |
| Gilead Sciences, INC. | $17.45 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $16.81 | 2024 | |
| Electromed, INC. | $15.59 | 2025 | Smartvest |
| Kyowa Kirin, INC. | $15.06 | 2023 | |
| Corcept Therapeutics | $14.99 | 2025 | Korlym |
| Sun Pharmaceutical Industries INC. | $14.41 | 2019 | |
| Acadia Pharmaceuticals INC | $13.75 | 2019 | |
| Circassia INC. | $13.44 | 2019 | |
| Almatica Pharma LLC | $13.28 | 2024 | Loreev Xr |
| Nestle Healthcare Nutrition INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.